Welcome to our dedicated page for Biogen SEC filings (Ticker: BIIB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Biogen Inc. (BIIB) SEC filings page on Stock Titan provides access to the company’s U.S. Securities and Exchange Commission disclosures, including current reports on Form 8-K and other key documents. As a Nasdaq-listed biotechnology company, Biogen uses these filings to report financial results, material events and governance matters that are important for investors evaluating its activities in neurology, rare diseases and immunology.
Recent Form 8-K filings show how Biogen communicates results of operations and financial condition, including quarterly earnings press releases and preliminary estimates of acquired in-process research and development, upfront and milestone expenses. The company explains that these expenses arise from collaboration and license agreements and are presented as a separate line item in its condensed consolidated statements of income. Other 8-K filings cover shareholder votes at the annual meeting, such as the election of directors and ratification of the independent registered public accounting firm.
Through this page, users can review Biogen’s SEC-reported information alongside Stock Titan’s AI-powered tools, which can help summarize lengthy filings and highlight key items such as collaboration-related charges, capital allocation decisions and governance outcomes. Investors interested in Biogen’s partnerships, pipeline investments and financial reporting practices can use these filings to understand how the company accounts for its research collaborations, including those involving antisense oligonucleotides, monoclonal antibodies and emerging modalities.
In addition to 8-Ks, this page can link to other Biogen filings available on EDGAR, such as annual reports on Form 10-K and quarterly reports on Form 10-Q, where the company provides more detailed discussion of its business, risk factors and financial statements. Together, these documents form the regulatory record that underpins fundamental analysis of BIIB.
Biogen Inc. announced a preliminary estimate for the quarter ended September 30, 2025: it expects approximately $2 million of acquired in‑process research and development, upfront and milestone expense. The company estimates this will reduce GAAP and non‑GAAP net income per diluted share for Q3 2025 by about ($0.01) per share.
Biogen began presenting this expense as a separate line item starting in the first quarter of 2025 to reflect costs tied to collaboration and license agreements, including upfront and milestone payments and, when applicable, premiums on equity securities and asset acquisitions of in‑process R&D. Results for the quarter have not been finalized and remain subject to financial statement closing procedures.
Sean Godbout, identified as a Director and the issuer's Chief Accounting Officer, reported changes in his beneficial ownership of BioGen Inc. (BIIB) on
Priya Singhal, Head of Development at Biogen Inc. (BIIB), reported a series of equity transactions dated 08/29/2025 and 09/02/2025. A grant of 1,669 restricted stock units (RSUs) vested (recorded as an acquisition at $0) increasing her beneficial ownership before sales to 7,096.1428 shares. On 08/29/2025 she sold 807 shares at $132.22 and on 09/02/2025 she sold 517 shares at $133.55, leaving her with 5,772.1428 shares following the reported transactions. The filing notes the RSU award was granted on September 1, 2022 and vests in three equal annual installments.
Biogen Inc. (BIIB) has filed a Form 144 notifying a proposed sale of 517 shares of common stock through Fidelity Brokerage Services. The filing lists an aggregate market value of $69,045.35 for the shares and states an approximate sale date of 09/02/2025 on NASDAQ. The shares were acquired on 09/01/2025 by restricted stock vesting from the issuer and payment is listed as compensation.
The filing shows 146,614,598 shares outstanding for the issuer. No securities sold in the past three months are reported and the filer represents there is no undisclosed material adverse information. The notice identifies Fidelity Brokerage Services LLC as the broker and includes the standard certification and signature/representation language required by Rule 144.
Biogen held its 2025 Annual Meeting of Stockholders on June 17, 2025, with three key matters put to vote. All eleven nominated directors were successfully elected to serve one-year terms until the 2026 annual meeting, with notable strong support for Lloyd Minor, Menelas Pangalos, and Monish Patolawala, each receiving over 114 million votes in favor.
Key voting outcomes include:
- Independent Auditor Appointment: PricewaterhouseCoopers LLP was ratified as the independent auditor for FY2025 with strong support (120,065,433 votes in favor)
- Say-on-Pay Vote: The executive compensation package was approved, though with more divided support - 78.5 million votes in favor versus 37.1 million against
The relatively split vote on executive compensation (67.8% approval) suggests some shareholder concerns about leadership remuneration. The high broker non-votes (10.2 million) across most items indicate significant holdings by institutional investors who did not provide voting instructions.
Form 4 overview: On 06/17/2025 Biogen (BIIB) director Menelas N. Pangalos received 2,370 restricted stock units (RSUs) at no cost. The units convert to common stock on the earlier of the company’s next annual meeting or 06/17/2026. After the award, the director beneficially owns 2,370 BIIB shares directly.
No shares were sold or disposed of; the filing reflects standard director compensation. Given Biogen’s large share count, the issuance is immaterial to dilution or valuation and therefore neutral for investors.
FAQ
What is the current stock price of Biogen (BIIB)?
What is the market cap of Biogen (BIIB)?
